B-Cell Lymphoblastic Leukemia/Lymphoma
Associated Genetic Biomarkers
NCI Definition: A neoplasm of lymphoblasts committed to the B-cell lineage, typically composed of small to medium-sized blast cells. When the neoplasm involves predominantly the bone marrow and the peripheral blood, it is called B acute lymphoblastic leukemia. When it involves nodal or extranodal sites, it is called B lymphoblastic lymphoma. (WHO, 2001) 
B-cell lymphoblastic leukemia/lymphomas most frequently harbor alterations in TP53, KRAS, CDKN2A, NRAS, and CREBBP .
TP53 Mutation, KRAS Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, and NRAS Mutation are the most common alterations in B-cell lymphoblastic leukemia/lymphoma .
There are 3 clinical trials for B-cell lymphoblastic leukemia/lymphoma, of which 3 are open and 0 are completed or closed. Of the trials that contain B-cell lymphoblastic leukemia/lymphoma as an inclusion criterion, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 3 (1 open).
CD19 is the most frequent gene inclusion criterion for B-cell lymphoblastic leukemia/lymphoma clinical trials .
Cytarabine, doxorubicin, and hydrocortisone are the most common interventions in B-cell lymphoblastic leukemia/lymphoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.